Establishment of Gemcitabine-resistant Mouse Pancreatic Ductal Adenocarcinoma Cell Line and Possible Therapeutic Agents
We established a novel GEM-resistant mPDAC model and identified MAOB as a promising therapeutic target. These findings provide a rationale for targeting MAOB-driven survival signals to overcome chemoresistance in refractory pancreatic cancer.
Authors
- Kimihiro Yamashita (ORCID: https://orcid.org/0000-0002-4208-7138)
- Yuki Ise
- K. Shimizu (ORCID: https://orcid.org/0009-0000-9179-4720)
- Takaaki Nishiyama
- Noriyuki Nishimura (ORCID: https://orcid.org/0000-0002-9000-4341)
- Kumiko Miyashita
- Yuichi Hori
- SHUN OHSAKA
- MAKOTO MIYOSHI
Institutions
- Kobe Medical Center (JP)
- Kobe University (JP)
Publication Details
- Journal
- Anticancer Research
- Published
- 2026-03-27
- DOI
- https://doi.org/10.21873/anticanres.18076
- Primary Topic
- Pancreatic and Hepatic Oncology Research
- Type
- article
- Field-Weighted Citation Impact
- 0.00